BAM
DNTH icon

Belpointe Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Belpointe Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-344
Closed -$4.37K – 1276
2023
Q1 		$4.37K Hold
344
– – ﹤0.01% 3065
2022
Q4 		$2.17K Buy
+344
New +$6.09K ﹤0.01% 3230

Other funds holding DNTH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Belpointe Asset Management's DNTH Position: Q2 2023 in Review

Belpointe Asset Management sold out of Dianthus Therapeutics (DNTH) in Q2 2023, closing a stake of 344 shares — an estimated $4.37K sold.

Belpointe Asset Management first reported a position in DNTH in Q4 2022 and held it in 2 quarters. The position peaked at $4.37K in Q1 2023. 46 funds tracked by Wall St. Rank hold DNTH as of Q2 2023.

  • Belpointe Asset Management reported no remaining Dianthus Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 344 Dianthus Therapeutics shares in Q2 2023, an estimated $4.37K.
  • Belpointe Asset Management first reported a position in Dianthus Therapeutics in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Dianthus Therapeutics position peaked at $4.37K in Q1 2023.
  • 46 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.